E014 Hypertrophy of the cerebral parasagittal dural space, an emerging neurofluid egress conduit, relates to disease severity in Huntington disease

<h3>Background/Aims</h3> Aberrant cerebrospinal fluid (CSF) flow and egress persist in many patients with Huntington’s disease (HD), and quantitation of these phenomena could inform mechanisms of disease progression and potentially assist with triaging patients for intrathecally-administered therapies. This work reports on the relevance of a recently-identified parasagittal dural (PSD) CSF egress pathway, using magnetic resonance imaging, to symptomatology across the spectrum of HD severity. <h3>Methods</h3> PSD was quantified using a recently-validated T2-weighted MRI and associated deep-learning segmentation in genetic-expanded (GE; n=57) and age-matched gene non-expanded (GNE; n=54) carriers. GE carriers were stratified by disease stage per HD-ISS criteria. CAP score and UHDRS total motor scores (TMS) were used to characterize disease burden and clinical symptom severity, respectively. Linear regression models and Spearman correlation were applied to assess GNE and GE-stage group-wise differences with PSD, and PSD relationship with disease burden, symptomatology, and relevant co-variates (significance criterion: p&lt;0.05). <h3>Results</h3> A significant increase of PSD volume in GE versus GNE carriers, in early (HD-ISS stages=0–1; p=0.046) and later (HD-ISS stages=2–3; p=0.019) stage was observed. PSD hypertrophy relates directly to CAP score (p=0.002) and TMS (p=0.001). These relationships were confirmed with linear regression models after controlling for age, sex, and intracranial volume. <h3>Conclusions</h3> PSD, a structure with emerging relevance to neurofluid egress and proteinopathy, directly relates to HD disease stage, burden, and clinical severity. Disease modification treatment trials, especially antisense oligomer trials, may interpret immune processes and treatment efficacy across the spectrum of diverse neurofluid kinetics within conventional and more novel PSD channels.

Authors

Institutions

Publication Details

Published
2024-09-01
DOI
https://doi.org/10.1136/jnnp-2024-ehdn.110
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

E014 Hypertrophy of the cerebral parasagittal dural space, an emerging neurofluid egress conduit, relates to disease severity in Huntington disease

Alexander Song, I Taylor, Elisa Catalina Parra Cancino, Colin D. McKnight et al.
Genetic Neurodegenerative Diseases
article

E014 Hypertrophy of the cerebral parasagittal dural space, an emerging neurofluid egress conduit, relates to disease severity in Huntington disease

Alexander Song, I Taylor, Elisa Catalina Parra Cancino, Colin D. McKnight, Manus J. Donahue, Ciaran Michael Considine, Daniel O. Claassen, Shuhei Shiino, Kilian Hett, Melanie Leguizamon
article en

Abstract

<h3>Background/Aims</h3> Aberrant cerebrospinal fluid (CSF) flow and egress persist in many patients with Huntington’s disease (HD), and quantitation of these phenomena could inform mechanisms of disease progression and potentially assist with triaging patients for intrathecally-administered therapies. This work reports on the relevance of a recently-identified parasagittal dural (PSD) CSF egress pathway, using magnetic resonance imaging, to symptomatology across the spectrum of HD severity. <h3>Methods</h3> PSD was quantified using a recently-validated T2-weighted MRI and associated deep-learning segmentation in genetic-expanded (GE; n=57) and age-matched gene non-expanded (GNE; n=54) carriers. GE carriers were stratified by disease stage per HD-ISS criteria. CAP score and UHDRS total motor scores (TMS) were used to characterize disease burden and clinical symptom severity, respectively. Linear regression models and Spearman correlation were applied to assess GNE and GE-stage group-wise differences with PSD, and PSD relationship with disease burden, symptomatology, and relevant co-variates (significance criterion: p&lt;0.05). <h3>Results</h3> A significant increase of PSD volume in GE versus GNE carriers, in early (HD-ISS stages=0–1; p=0.046) and later (HD-ISS stages=2–3; p=0.019) stage was observed. PSD hypertrophy relates directly to CAP score (p=0.002) and TMS (p=0.001). These relationships were confirmed with linear regression models after controlling for age, sex, and intracranial volume. <h3>Conclusions</h3> PSD, a structure with emerging relevance to neurofluid egress and proteinopathy, directly relates to HD disease stage, burden, and clinical severity. Disease modification treatment trials, especially antisense oligomer trials, may interpret immune processes and treatment efficacy across the spectrum of diverse neurofluid kinetics within conventional and more novel PSD channels.

Vanderbilt University (US), Vanderbilt University Medical Center (US)
Good health and well-being
Openalex Percentile: Top 85%
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.